ADMA BIOLOGICS, INC.

ADMA Biologics reported a 10.5% increase in Q2 net income to $37.8 million and a 40% rise in H1 diluted EPS to $0.35. The company saw a substantial improvement in net cash provided by operating activities, reaching $87.8 million for the first half of 2026. This period also included a significant acquisition of treasury stock totaling $155.2 million and an increase in long-term debt.

ADMA Biologics reported strong second quarter 2026 financial results, with total revenue increasing 2% year-over-year to $124.4 million, driven by a 24% surge in ASCENIV revenue to $102.9 million. GAAP net income rose 11% to $37.8 million, and Adjusted EBITDA grew 22% to $61.8 million. The company reiterated its full-year 2026 financial guidance, highlighting accelerating ASCENIV demand, stabilizing BIVIGAM utilization, and ongoing progress in its SG-001 development program. ADMA also continued its share repurchase program, buying back 7.1 million shares in the quarter.

ADMA Biologics reported strong financial performance for Q1 2026, with net income increasing to $45.3 million and diluted EPS rising to $0.19, despite a slight dip in revenues. The company significantly improved its gross profit and income from operations, and generated substantial positive cash flow from operating activities. Additionally, ADMA completed the sale of three plasma collection centers, recognizing an $8.0 million gain, and executed a $130.2 million treasury stock acquisition.

ADMA Biologics reported Q1 2026 financial results, with total revenue of $114.5 million, flat year-over-year. Despite competitive market dynamics, Adjusted Net Income grew 22% to $40.7 million and Adjusted EBITDA increased 24% to $59.7 million. The company updated its FY 2026 outlook, expecting total revenue of $530-$560 million, and withdrew long-term guidance. An internal review by the Audit Committee concluded no improper channel stuffing or undisclosed related party transactions.

ADMA Biologics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application for ASCENIV™. This approval expands the drug's label to include pediatric immune compromised patients two years of age and older, a significant change from the previous restriction to patients aged 12 years and older. This allows ADMA to actively address the treatment needs of a younger patient population with primary humoral immunodeficiency.

ADMA Biologics, Inc. announced it will report its first quarter 2026 financial results on May 6, 2026, after the U.S. financial markets close. The company's management team will host a live conference call and audio webcast on the same date at 4:30 p.m. ET to discuss the financial results and provide other company updates. Registration is required for participants to access the call.